Results 331 to 340 of about 3,169,653 (411)
Some of the next articles are maybe not open access.
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder
Annals of Neurology, 2020To evaluate the dose–response relationship of daridorexant, a new dual orexin receptor antagonist, on sleep variables in subjects with insomnia disorder.
Y. Dauvilliers +6 more
semanticscholar +1 more source
Vasopressin-Receptor Antagonists
Future Cardiology, 2010Despite a crucial role in body fluid homeostasis, elevated vasopressin levels can also be pathological in conditions such as congestive heart failure, liver cirrhosis and the syndrome of inappropriate antidiuretic hormone secretion. The result of elevated vasopressin is renal water retention and hyponatremia, a low serum sodium concentration ...
Ewout J. Hoorn, Robert Zietse
openaire +3 more sources
Melanocortins and their Receptors and Antagonists
Current Drug Targets, 2003The melanocortins are a group of small protein hormones derived by post-translational cleavage of the proopiomelanocortin (POMC) gene product. The known melanocortin hormones include alpha-melanocyte stimulating hormone (MSH), beta-MSH, gamma-MSH and adrenocorticotropic hormone (ACTH).
Voisey, J, Carroll, L, van Daal, A
openaire +4 more sources
Pharmaceutical Patent Analyst, 2012
The orexin neuropeptides bind to two G protein-coupled receptors, orexin-1 and -2. Small-molecule antagonism of the receptors has potential therapeutic utility in a number of areas, most notably insomnia, for which the most advanced dual orexin receptor antagonist has now completed clinical trials.
Miles Congreve +4 more
openaire +3 more sources
The orexin neuropeptides bind to two G protein-coupled receptors, orexin-1 and -2. Small-molecule antagonism of the receptors has potential therapeutic utility in a number of areas, most notably insomnia, for which the most advanced dual orexin receptor antagonist has now completed clinical trials.
Miles Congreve +4 more
openaire +3 more sources
Receptors for calcium antagonists
The American Journal of Cardiology, 1988Calcium antagonists have been divided into 3 different subclasses represented by nifedipine, verapamil and diltiazem. These drugs have different pharmacologic effects and are not interchangeable. Previous studies suggested that all calcium antagonists bind to a 170 kd polypeptide (now called the alpha 2 subunit of the voltage-dependent calcium channel).
Edward McKenna +2 more
openaire +3 more sources